What is claimed is:

1. A formulation comprising:

two or more of an extract of *Ganoderma lucidum*, an extract of *Salvia miltiorrhiza*, an extract of *Scutellaria barbata*, and an extract of *Scutellaria baicalensis* wherein each extract comprises about 1 to about 90 percent by weight; and a combination of emulsifying agents comprising: Cremophor EL, oleic acid and labrasol, and wherein the extracts are made in a non-alcoholic organic solvent.

2. The formulation of claim 1 further comprising an antioxidant.

3. The formulation of claim 2 wherein the antioxidant is selected from ascorbic acid and alpha tocopherol.

4. The formulation of claim 1 further comprising a diluent.

5. The formulation of claim 4 wherein the diluent is soya oil.

6. The formulation of claim 1 wherein the non-alcoholic organic solvent is an ester.

7. The formulation of claim 6 wherein the ester is ethyl acetate.

8. The formulation according to any of claims 1-7, wherein the formulation exhibits increased bioavailability compared to a formulation without an emulsifying agent.

9. The formulation according to any of claims 1-7, wherein the formulation exhibits increased maximum tolerated dose (MTD) compared to a formulation without an emulsifying agent.

10. The formulation according to claim 1, comprising:

an ethyl acetate extract of *Ganoderma lucidum*, an ethyl acetate extract of *Salvia miltiorrhiza*, and an ethyl acetate extract of *Scutellaria barbata* wherein each extract comprises about 1 to about 90 percent by weight;

a combination of emulsifying agents comprising Cremophor EL, oleic acid and labrasol;

an antioxidant selected from ascorbic acid and alpha tocopherol; and

a diluent selected from soya oil.

11. The formulation according to any of claims 1 through 10, further comprising a chemotherapeutic agent.

12. The formulation of claim 11, wherein the chemotherapeutic agent is selected from carboplatin, navelbine® (vinorelbine), anthracycline (Doxil), lapatinib (GW57016), Herceptin®, gemcitabine (Gemzar®), capecitabine (Xeloda®), Alimta®, cisplatin, 5-fluorouracil, epirubicin, cyclophosphamide, Avastin®, Velcade®, paclitaxel and docetaxel.

13. The formulation of claim 11, wherein the chemotherapeutic agent is selected from the group consisting of antimetabolites, nucleoside analogs, platinum-based agents, alkylating agents, tyrosine kinase inhibitors, anthracycline antibiotics, vinca alkloids, proteasome inhibitors, macrolides, and topoisomerase inhibitors.

14. Use of the formulation according to any one of claims 1-12 in the manufacture of a medicament for the treatment of cancer in a subject suspected of having cancer.

15. The use according to claim 14, wherein the formulation comprises 0.1 to 100 mg of an active ingredient consisting of two or more of an extract of *Ganoderma lucidum*, an extract of *Salvia miltiorrhiza*, an extract of *Scutellaria barbata*, and an extract of *Scutellaria baicalensis*.

16. The use according to claim 15, wherein 1, 1.5, 2. 2.5, 3, 4, or 5 g of the active ingredient is to be administered daily.

17. The use according to claim 15, wherein the formulation is to be administered in 7, 14 or 28 day cycles of 1, 2, 3, 4, 5, or 6 cycles.

18. The use according to claim 14, wherein a chemotherapeutic agent is to be administered either in the same formulation or separately as part of a therapeutic regimen.

19. The use according to claim 18, wherein the chemotherapeutic agent is selected from carboplatin, navelbine® (vinorelbine), anthracycline (Doxil), lapatinib (GW57016), Herceptin®, gemcitabine (Gemzar®), capecitabine (Xeloda®), Alimta®, cisplatin, 5-fluorouracil, epirubicin, cyclophosphamide, Avastin®, velcade®, paclitaxel and docetaxel.

20. The use according to claim 18, wherein the chemotherapeutic agent is selected from the group consisting of antimetabolites, nucleoside analogs, platinum-based agents, alkylating agents, tyrosine kinase inhibitors, anthracycline antibiotics, vinca alkloids, proteasome inhibitors, macrolides, and topoisomerase inhibitors.